A multinational, phase 2, randomised, adaptive protocol to evaluate immunogenicity and reactogenicity of different COVID-19 vaccines administration in older aldults (=75) already vaccinated against SARS-COV-2 (EU-COVAT-1 Aged)
IP: ESPERANZA MARÍA ROMERO RODRIGUEZ